Historically,<unk>  Panniculitis-like T-cell<unk> , as with other types of T-cell<unk> , was treated similarly to B-cell<unk> s. However, in recent years, scientists have developed techniques to better recognize the different types of<unk> s, such as PTCL. It is now understood that PTCL behaves differently from B-cell<unk> s and therapies are being developed that specifically target these types of<unk> . Currently, however, there are no drugs approved by the U.S. Food and Drug Administration (FDA) specifically for PTCL. There are two drugs, Pralatrexate and Romidepsin, which are both approved by the FDA for relapsed or refractory T cell<unk> . Anthracycline-containing chemotherapy regimens are commonly offered as the initial therapy. Some patients may receive an autologous or allogeneic stem cell transplant. Novel approaches to the treatment of PTCL in the relapsed or refractory setting are under investigation. CHOP or CHOP-like regimens have been used.
Subcutaneous T-cell lymphoma
Primary cutaneous immunocytoma
Generalized eruptive histiocytoma
Langerhans cell sarcoma
Primary cutaneous adenoid cystic carcinoma
Paraneoplastic acrokeratosis
Cutaneous B-cell lymphoma
Sebaceous lymphadenoma